The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.
The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.
[EN] THERAPEUTIC KINASE MODULATORS<br/>[FR] MODULATEURS DE KINASE THÉRAPEUTIQUES
申请人:CYLENE PHARMACEUTICALS INC
公开号:WO2009097014A2
公开(公告)日:2009-08-06
The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.
Synthesis and SAR of inhibitors of protein kinase CK2: Novel tricyclic quinoline analogs
作者:Mustapha Haddach、Fabrice Pierre、Collin F. Regan、Cosmin Borsan、Jerome Michaux、Eric Stefan、Pauline Kerdoncuff、Michael K. Schwaebe、Peter C. Chua、Adam Siddiqui-Jain、Diwata Macalino、Denis Drygin、Sean E. O’Brien、William G. Rice、David M. Ryckman
DOI:10.1016/j.bmcl.2011.11.087
日期:2012.1
Protein kinase CK2 is a potential drug target for many diseases including cancer and inflammation disorders. The crystal structure of clinical candidate CX-4945 1 with CK2 revealed an indirect interaction with the protein through hydrogen bonding between the NH of the 3-chlorophenyl amine and a water molecule. Herein, we investigate the relevance of this hydrogen bond by preparing several novel tricyclic derivatives lacking a NH moiety at the same position. This SAR study allowed the discovery of highly potent CK2 inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.